Research Topics
Species | Leslie CitromeSummaryAffiliation: Nathan Kline Institute Country: USA Publications
| Collaborators
|
Detail Information
Publications
Commentary: bipolar disorder is a potentially fatal diseaseLeslie Citrome
New York State University School of Medicine, New York
Postgrad Med 117:9-11. 2005
Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinionLeslie Citrome
New York University School of Medicine, New York City, NY, USA
Expert Opin Drug Metab Toxicol 6:1551-64. 2010..Iloperidone is a newly commercialized second-generation (atypical) antipsychotic approved for the acute treatment of schizophrenia in adults...
Schizophrenia, obesity, and antipsychotic medications: what can we do?Leslie Citrome
New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Postgrad Med 120:18-33. 2008..At the very least, a "small-steps approach" to managing weight should be offered to all patients who are overweight or obese...
Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risksLeslie Citrome
New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Expert Rev Neurother 8:1079-91. 2008..The examples provided are extensions to the initially published NNT and NNH analyses conducted by the first author...
Loss aversion in schizophreniaFabien Tremeau
Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, United States
Schizophr Res 103:121-8. 2008..Loss aversion is conceived as an affective interference in cognitive processes such as judgment and decision-making. Loss aversion in non-risky choices has not been studied in schizophrenia...
Current guidelines and their recommendations for prolactin monitoring in psychosisLeslie Citrome
New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
J Psychopharmacol 22:90-7. 2008..These decisions would be within the context of considering other adverse events as well as the overall effectiveness of the antipsychotic medication being used...
Did CATIE influence antipsychotic use?Leslie Citrome
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Psychiatr Serv 59:476. 2008
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safetyLeslie Citrome
Department of Psychiatry, New York University School of Medicine, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
J Clin Psychiatry 68:1876-85. 2007..To compare the efficacy and safety of the intramuscular formulations of ziprasidone, olanzapine, and aripiprazole in treating agitation...
The effectiveness criterion: balancing efficacy against the risks of weight gainLeslie Citrome
Department of Psychiatry, New York University School of Medicine, New York, USA
J Clin Psychiatry 68:12-7. 2007..Predictors of weight gain for olanzapine are reviewed for schizophrenia and bipolar disorder, as is a monitoring plan applicable for all patients receiving antipsychotic therapy...
Introduction: weighing the evidence: weight management insights for treating major mental illnessLeslie Citrome
Department of Psychiatry, New York University School of Medicine, New York, USA
J Clin Psychiatry 68:4. 2007
Reducing inpatient aggression: does paying attention pay off?Karen A Nolan
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Psychiatr Q 79:91-5. 2008..Video technology can improve detection, but is labor-intensive and costly. We examined the effectiveness of interventions to improve reporting on a secure inpatient research unit equipped with audio/video surveillance...
Atypical antipsychotics, elderly patients, and mortality riskLeslie Citrome
New York University School of Medicine and Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
South Med J 100:964-5. 2007
Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostilityLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
Int Clin Psychopharmacol 22:356-62. 2007..In conclusion, although patients receiving combination treatment were more likely to complete the study, we were unable to detect a meaningful advantage for combination therapy as measured by rating scales...
Show me the evidence: using number needed to treatLeslie Citrome
Department of Psychiatry, New York University School of Medicine, USA
South Med J 100:881-4. 2007....
Pharmacokinetics of aripiprazole and concomitant carbamazepineLeslie Citrome
Nathan S Kline Institute for Psychiatric Research and Rockland Psychiatric Center, Orangeburg, NY 10962, USA
J Clin Psychopharmacol 27:279-83. 2007..Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from combination therapy, aripiprazole dose should then be reduced...
Datapoints: The ups and downs of dosing second-generation antipsychoticsLeslie Citrome
Department of Psychiatry, New York University School of Medicine, New York City, USA
Psychiatr Serv 58:11. 2007
Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004Leslie Citrome
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Psychiatr Serv 57:1132-9. 2006....
A new rating scale for negative symptoms: the Motor-Affective-Social ScaleFabien Tremeau
Clinical Research and Evaluation Facility, Nathan S Kline Institute for Psychiatric Research and Rockland Psychiatric Center, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Psychiatry Res 160:346-55. 2008..Future research that includes the use of the MASS with other patient populations and that investigates the scale's sensitivity during clinical trials should be performed...
Public-academic partnerships: integrating state psychiatric hospital treatment and clinical researchLeslie Citrome
Nathan S Kline Institute forPsychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY 10962, USA
Psychiatr Serv 59:958-60. 2008..Kline Institute for Psychiatric Research, colocated on the same campus as Rockland Psychiatric Center, each of which is an independent facility operated by the New York State Office of Mental Health...
Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?Leslie Citrome
New York University School of Medicine, Department of Psychiatry, New York, USA
Expert Rev Neurother 9:55-71. 2009....
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmedLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Postgrad Med 122:39-48. 2010..To describe the efficacy and safety of adjunctive aripiprazole, olanzapine, and quetiapine for major depressive disorder...
Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adultsLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Expert Rev Neurother 10:1031-7. 2010..e., more robust) NNT for quetiapine in terms of proportions of subjects experiencing a mood event (NNT: 4), but a higher incidence of bodyweight gain of at least 7% from baseline...
Spirituality, schizophrenia, and state hospitals: program description and characteristics of self-selected attendees of a spirituality therapeutic groupNadine Revheim
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Psychiatr Q 81:285-92. 2010..These findings lend support for offering spirituality groups and positive coping during recovery from psychiatric disabilities...
Citability of original research and reviews in journals and their sponsored supplementsLeslie Citrome
Department of Psychiatry, New York University School of Medicine, New York, New York, United States of America
PLoS ONE 5:e9876. 2010..It is unknown if their contents are cited as often. The objective of this study was to quantify the citability of original research and reviews contained in supplements and compare it with that for the parent journal...
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilitiesLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Schizophr Res 119:153-9. 2010..This study aimed to characterize the inpatient utilization of depot antipsychotics...
Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorderLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
Schizophr Res 115:115-20. 2009..The purpose of this study is to evaluate the relationship between maximum dose of ziprasidone and time to discontinuation in the treatment of schizophrenia/schizoaffective disorder and bipolar disorder in clinical practice...
Using oral ziprasidone effectively: the food effect and dose-responseLeslie Citrome
Department of Psychiatry, Nathan S Kline Institute for Psychiatric Research, New York University School of Medicine, Orangeburg, NY 10962, USA
Adv Ther 26:739-48. 2009..Provided that an adequate dose of ziprasidone is prescribed, and administered with a 500 kcal meal, ziprasidone can be effectively used to control symptoms without the long-term liabilities of metabolic side effects...
How dosing of ziprasidone in a state hospital system differs from product labelingLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, Orangeburg, N Y 10962, USA
J Clin Psychiatry 70:975-82. 2009....
Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?Leslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Expert Rev Neurother 9:1045-58. 2009..This is somewhat supported by double-blind, controlled clinical trial evidence, but only for selected patients with severe and/or persistent symptoms...
Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medicationsLeslie Citrome
New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Curr Drug Saf 4:229-37. 2009..This supplements, but does not replace, information reported directly in clinical trial reports...
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJean Pierre Lindenmayer
New York University School of Medicine, New York, N Y 10035, USA
J Clin Psychiatry 70:990-6. 2009..To examine the impact of medication nonadherence on treatment outcome in schizophrenia and potential risk factors for nonadherence...
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentrationLeslie Citrome
Clinical Research and Evaluation Facility, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
J Clin Psychopharmacol 29:278-83. 2009..In conclusion, olanzapine pharmacokinetics of doses up to 40 mg/d was generally consistent with prior findings in studies with fewer subjects and/or lower doses...
Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based studyKaren A Nolan
Clinical Research Division, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, 10962, USA
Psychiatr Q 80:167-72. 2009..Responses to aggressive events do not take causes into account. It is possible that consideration of the reasons for the aggressive behavior might yield more targeted interventions...
Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trialsLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Schizophr Res 111:39-45. 2009..This study examines the relationship of ziprasidone dose and all-cause discontinuation in randomized clinical trials in patients with an acute exacerbation of schizophrenia or schizoaffective disorder...
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidolMenahem Krakowski
Nathan Kline Institute for Psychiatric Research, Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States
Schizophr Res 110:95-102. 2009..The goal of this study was to assess the effects of clozapine and olanzapine in comparison to the first-generation agent haloperidol on these metabolic parameters in aggressive patients with schizophrenia...
Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorderLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Schizophr Res 108:238-44. 2009..This has been reported for olanzapine and quetiapine, where higher doses are commonly used. This may be the case for ziprasidone as well...
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorderMenahem I Krakowski
Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Arch Gen Psychiatry 63:622-9. 2006..Violent behavior of patients with schizophrenia prolongs hospital stay and interferes with their integration into the community. Finding appropriate treatment of violent behaviors is of primary importance...
Antipsychotic-induced weight gain and therapeutic response: a differential associationPal Czobor
Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
J Clin Psychopharmacol 22:244-51. 2002..These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain...
Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatientsLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
Psychiatr Serv 55:1006-13. 2004....
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioningLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
Postgrad Med 116:49-51, 55-9, 63. 2004..In this article, the authors discuss the advantages and side effects of these agents and present a guide to help physicians choose the optimal drug in the most favorable formulation for each patient...
New treatments for agitationLeslie Citrome
S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Psychiatr Q 75:197-213. 2004..This includes newer formulations of novel antipsychotics such as liquids and rapidly disintegrating tablets, as well as intramuscular preparations...
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidolJan Volavka
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
J Clin Psychopharmacol 24:225-8. 2004..Clozapine appears to have superior antiaggresive effects in treatment-resistant patients; this superiority develops after the patient has been exposed to an adequate dose regimen...
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophreniaJean Pierre Lindenmayer
Nathan Kline Institute, Orangeburg, N Y, USA
J Clin Psychiatry 65:551-6. 2004..We are exploring whether this expanded clinical efficacy can also be seen in patients with treatment-resistant schizophrenia...
A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophreniaLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
J Clin Psychopharmacol 24:255-9. 2004....
COMT158 polymorphism and hostilityJan Volavka
Nathan Kline Institute, Orangeburg, New York 10982, USA
Am J Med Genet B Neuropsychiatr Genet 127:28-9. 2004..The Met-Met homozygotes (N = 7) were found to have significantly higher levels of hostility than the other patients (N = 53). The hypothesis was thus supported. The finding should be replicated in a larger sample...
Schizophrenia and valproateLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Psychopharmacol Bull 37:74-88. 2003..It is anticipated that future research will focus on the new extended-release formulation of divalproex that can be administered on a once-daily basis...
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidoneLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Psychiatr Serv 55:290-4. 2004....
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidolJan Volavka
Nathan Kline Institute, Orangeburg, NY 10982, USA
J Clin Psychiatry 65:57-61. 2004....
Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in menMary Ann Richardson
Division of Movement Disorders and Molecular Psychiatry, Nathan S Kine Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Am J Psychiatry 160:1117-24. 2003..The efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was tested...
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychoticsJean Pierre Lindenmayer
Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
Am J Psychiatry 160:290-6. 2003....
Atypical antipsychotics for acute agitation. New intramuscular options offer advantagesLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY 10962, USA
Postgrad Med 112:85-8, 94-6. 2002..In addition, development of depot preparations of atypical antipsychotics is progressing rapidly. These products may further revolutionize the emergency and postemergency care of psychotic patients...
Use of mood stabilizers among patients with schizophrenia, 1994-2001Leslie Citrome
Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Psychiatr Serv 53:1212. 2002
Optimal dosing of atypical antipsychotics in adults: a review of the current evidenceLeslie Citrome
Department of Psychiatry, New York University, New York, N Y, USA
Harv Rev Psychiatry 10:280-91. 2002....
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorderRobert M Bilder
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Am J Psychiatry 159:1018-28. 2002....
The many faces of bipolar disorder. How to tell them apartLeslie Citrome
New York University School of Medicine, New York, USA
Postgrad Med 117:15-6, 19-23. 2005..Effective pharmacotherapy and maintenance monitoring are critical in order to minimize the risk of relapse and associated disability, morbidity, and mortality...
Toward convergence in the medication treatment of bipolar disorder and schizophreniaLeslie Citrome
Department of Psychiatry, New York University School of Medicine, NY, USA
Harv Rev Psychiatry 13:28-42. 2005....
Metabolic syndrome and cardiovascular diseaseLeslie Citrome
New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
J Psychopharmacol 19:84-93. 2005..Ongoing monitoring for all components of the metabolic syndrome is necessary. Individuals at high risk require multimodal interventions, including lifestyle interventions and targeted medications as appropriate...
Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study dataLeslie Citrome
Nathan S Kline Institute for Psychiatric Research and the New York University School of Medicine, Orangeburg, NY 10962, USA
J Clin Psychiatry 67:638-42. 2006..The objective was to determine the effects of sequential intramuscular/oral ziprasi-done on hostility...
Do guidelines for severe mental illness promote physical health and well-being?Leslie Citrome
New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
J Psychopharmacol 19:102-9. 2005....
Metabolic issues in patients with severe mental illnessLeslie Citrome
New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
South Med J 98:714-20. 2005..Collaborative treatment between a psychiatrist and an endocrinologist is encouraged. The primary care physician may be required to fulfill both roles...
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorderJan Volavka
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
Am J Psychiatry 159:255-62. 2002....
Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitusLeslie Citrome
New York University School of Medicine, NY, USA
Int J Neuropsychopharmacol 8:147-51. 2005
The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illnessSerdar M Dursun
J Psychopharmacol 22:3-5. 2008
The psychopharmacology of violence with emphasis on schizophrenia, part 2: long-term treatmentLeslie Citrome
Department of Psychiatry, New York University School of Medicine, NY, USA
J Clin Psychiatry 68:331-2. 2007
The psychopharmacology of violence with emphasis on schizophrenia, part 1: acute treatmentLeslie Citrome
Department of Psychiatry, New York University School of Medicine, New York, NY, USA
J Clin Psychiatry 68:163-4. 2007
Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophreniaBruce J Kinon
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 26:632-7. 2006....
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch studyJean Pierre Lindenmayer
Psychopharmacology Research Unit, Manhattan Psychiatric Center, Wards Island, NY 10035, USA
J Clin Psychiatry 63:931-5. 2002....
Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studiesLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
J Clin Psychiatry 66:1512-6. 2005..The purpose of this article is to review the past and present dosing patterns of quetiapine for the treatment of schizophrenia...
Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE studyWilliam M Glazer
Glazer Medical Solutions, Menemsha, MA, USA
CNS Spectr 11:1-13; quiz 14. 2006....
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studiesJan Volavka
The Nathan Kline Institute and New York University, 140 Old Orangeburg Road, Orangeburg, N Y 10962, USA
J Clin Psychiatry 66:1362-6. 2005..The objective was to determine the effects of aripiprazole on hostility...
Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trialsWilliam M Greenberg
Department of Psychiatry, New York University School of Medicine, New York, NY, USA
CNS Drug Rev 13:137-77. 2007....
Early predictors of substantial weight gain in bipolar patients treated with olanzapineIlya Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 26:316-20. 2006..Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation...
Latest therapies for bipolar disorder. Looking beyond lithiumJoseph F Goldberg
Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York, USA
Postgrad Med 117:25-6, 29-32, 35-6. 2005..Maintenance treatments that have received FDA approval include olanzapine and lamotrigine. Off-label use of adjunctive medications may be required to target residual symptoms...
Antipsychotics and hyperprolactinaemia: clinical recommendationsRobert C Peveler
University of Southampton, Royal South Hants Hospital, Southampton, UK
J Psychopharmacol 22:98-103. 2008..We hope it will add to the debate about this topic...
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophreniaDaniel J Muller
Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R30, Toronto, Ont M5T 1R8, Canada
Neurosci Lett 379:81-9. 2005..Weight changes do not seem to be associated with polymorphism of the SNAP-25 gene, however, replication in independent samples is warranted...
Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trialsDonald C Goff
Massachusetts General Hospital, Harvard Medical School, 25 Staniford Street, Boston, MA 02114, USA
J Clin Psychopharmacol 27:582-9. 2007..We sought to evaluate the potential role of lamotrigine augmentation in schizophrenia patients resistant to atypical antipsychotic medication...
Valproate: do formulations matter?Leslie Citrome
J Clin Pharm Ther 33:457; author reply 458. 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose studyBruce J Kinon
Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 28:392-400. 2008....
Pharmacokinetics of aripiprazole and concomitant lithium and valproateLeslie Citrome
Nathan S. Kline Institute for Psychiatic Research and the Rockland Psychiatric Center, Orangeburg, NY 10962, USA
J Clin Pharmacol 45:89-93. 2005..Therapeutic doses of lithium and divalproex had no clinically significant effects on the pharmacokinetics of aripiprazole in patients with schizophrenia or schizoaffective disorder...
Monotherapy versus polypharmacy for hospitalized psychiatric patientsLeslie Citrome
Am J Psychiatry 162:631; author reply 632-3. 2005
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluationJan Volavka
Schizophr Res 76:127-9. 2005
Dosing of second-generation antipsychotic medication in a state hospital systemLeslie Citrome
J Clin Psychopharmacol 25:388-91. 2005
Best clinical practice with ziprasidone IM: update after 2 years of experienceDan L Zimbroff
Pacific Clinical Research Medical Group, Upland, California 91786, USA
CNS Spectr 10:1-15. 2005..Additional trials of ziprasidone IM in agitated patients in a variety of clinical setting are warranted to generate comparative risk/benefit data with conventional agents and other second-generation antipsychotics...
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophreniaRobert M Bilder
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Biol Psychiatry 52:701-7. 2002....
